Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-Based Adjuvant Chemoradiation in Resected Pancreatic Adenocarcinoma
NCT00059826Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Mar 2003
- Primary completion
- Jul 2007
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of interferon alfa-2b in pancreatic adenocarcinoma (PDAC), sponsored by Cancer and Leukemia Group B. Primary endpoint: Overall Survival at 18 months. Started Mar 2003; status: completed.
02
Drugs
interferon alfa-2b
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00059826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00059826.